Pipeline

Innovation is in GenSci's DNA. GenSci advances a robust, innovative portfolio across four therapeutic areas: endocrinology & metabolism, women's health, immunology & respiratory diseases, and oncology.

The pipeline is updated quarterly. Last updated December 2025.
The pipeline is approved in at least one major market, such as China, USA and/or EU.
Only selected pipeline molecules are presented here.

Immunology / Respiratory Pipeline

Molecule

Indication(s)

Target(s)

IND

Phase Ⅰ

Phase Ⅱ

Phase Ⅲ

Registration

Launch

Firsekibart

GA

IL-1β

Firsekibart

sJIA

IL-1β

Firsekibart

EM, CTD-LD, Prevention of gout flares in the intercritical period

IL-1β

Firsekibart

Uveitis

IL-1β

GenSci098

TED

TSHR

GenSci120

RA, SLE, IBD, pSS

PD-1

GenSci136

IgAN, SLE, gMG, pSS

BAFF/APRIL

GenSci124

CF

CFTR

Immunology / Respiratory Pipeline

- IND
- Phase Ⅰ
- Phase Ⅱ
- Phase Ⅲ
- Registration
- Launch
- Firsekibart
  
  GA
  
  IL-1β
- Firsekibart
  
  sJIA
  
  IL-1β
- Firsekibart
  
  EM, CTD-LD, Prevention of gout flares in the intercritical period
  
  IL-1β
- Firsekibart
  
  Uveitis
  
  IL-1β
- GenSci098
  
  TED
  
  TSHR
- GenSci120
  
  RA, SLE, IBD, pSS
  
  PD-1
- GenSci136
  
  IgAN, SLE, gMG, pSS
  
  BAFF/APRIL
- GenSci124
  
  CF
  
  CFTR